Activation of peroxisome proliferator-activated receptor gamma inhibits osteoprotegerin gene expression in human aortic smooth muscle cells.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Biochemical and Biophysical Research Communications - BBRC

• Publication date

  2002-06-14

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0006-291X(02)00533-8PMID 12056809
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function.

  2002cited by this paper
• The role of PPAR-γ in macrophage differentiation and cholesterol uptake

  2001cited by this paper
• The role of PPAR-gamma in macrophage differentiation and cholesterol uptake.

  2001cited by this paper
• Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women.

  2001cited by this paper
• Platelet-Derived Growth Factor Promotes the Expression of Peroxisome Proliferator-Activated Receptor &ggr; in Vascular Smooth Muscle Cells by a Phosphatidylinositol 3-Kinase/Akt Signaling Pathway

  2001cited by this paper
• Peroxisome Proliferator-activated Receptor γ Inhibits Transforming Growth Factor β-induced Connective Tissue Growth Factor Expression in Human Aortic Smooth Muscle Cells by Interfering with Smad3*

  2001cited by this paper
• Osteoprotegerin: a link between osteoporosis and arterial calcification?

  2001cited by this paper
• Transcriptional Mechanisms of Bone Morphogenetic Protein-induced Osteoprotegrin Gene Expression*

  2001cited by this paper
• Peroxisome proliferator-activated receptor gamma and metabolic disease.

  2001cited by this paper
• PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ∞ AND METABOLIC DISEASE

  2001cited by this paper
• Smooth Muscle Cell Phenotypic Transition Associated With Calcification: Upregulation of Cbfa1 and Downregulation of Smooth Muscle Lineage Markers

  2001cited by this paper
• Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes.

  2001cited by this paper
• Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis

  2000cited by this paper
• Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.

  2000cited by this paper
• Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells.

  2000cited by this paper
• Expression and function of PPARgamma in rat and human vascular smooth muscle cells.

  2000cited by this paper
• Peroxisome proliferator-activated receptor (PPAR)-gamma expression in human vascular smooth muscle cells: inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-gamma activator troglitazone.

  2000cited by this paper
• Activation of Peroxisome Proliferator-activated Receptor-γ Pathway Inhibits Osteoclast Differentiation*

  2000cited by this paper
• Peroxisome proliferator‐activated receptors in the cardiovascular system

  2000cited by this paper
• The PPARs: from orphan receptors to drug discovery.

  2000cited by this paper
• 15-Deoxy-Δ12,14-prostaglandin J2 inhibits multiple steps in the NF-κB signaling pathway

  2000cited by this paper
• Peroxisome proliferator–activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor–deficient mice

  2000cited by this paper
• Expression and Function of PPARγ in Rat and Human Vascular Smooth Muscle Cells

  2000cited by this paper
• Osteoprotegerin Is an αvβ3-induced, NF-κB-dependent Survival Factor for Endothelial Cells*

  2000cited by this paper
• Peroxisome proliferator-activated receptor (PPAR)-γ expression in human vascular smooth muscle cells: inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-γ activator troglitazone☆

  2000cited by this paper
• 15-deoxy Δ^ -PGJ2 inhibits multiple steps in the NF-kappaB signaling pathway

  2000cited by this paper
• Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma.

  1999cited by this paper
• Orphan nuclear receptors: shifting endocrinology into reverse.

  1999cited by this paper
• osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.

  1998cited by this paper
• The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation

  1998cited by this paper
• Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.

  1998cited by this paper
• The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation.

  1998cited by this paper
• Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells.

  1998cited by this paper
• Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

  1997cited by this paper
• Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia.

  1996cited by this paper
• Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques.

  1993cited by this paper
• Bone morphogenetic protein expression in human atherosclerotic lesions.

  1993cited by this paper
• Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors.

  1992cited by this paper
• Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators

  1990cited by this paper

• Osteoprotegerin as an Emerging Biomarker of Carotid Artery Stenosis? A Scoping Review with Meta-Analysis

  2025cites this paper
• Osteoprotegerin mediates adipogenesis in obesity

  2024cites this paper
• Genetic and Epigenetic Mechanisms Underlying Vascular Smooth Muscle Cell Phenotypic Modulation in Abdominal Aortic Aneurysm

  2020cites this paper
• The Role of Osteoprotegerin as a Cardioprotective Versus Reactive Inflammatory Marker: the Chicken or the Egg Paradox

  2018cites this paper
• Osteoprotegerin and 25-hydroxy vitamin D levels in patients with diabetic foot.

  2018cites this paper
• Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease

  2016cites this paper
• Comparative effects of metformin and pioglitazone on fetuin-A and osteoprotegerin concentrations in patients with newly diagnosed diabetes: A randomized clinical trial.

  2015cites this paper
• Osteoprotegerin Deficiency Limits Angiotensin II–Induced Aortic Dilatation and Rupture in the Apolipoprotein E–Knockout Mouse

  2014cites this paper
• Correction: TRAIL-Deficiency Accelerates Vascular Calcification in Atherosclerosis via Modulation of RANKL

  2013cites this paper
• in vitro and in vivo Osteoprotegerin increases leukocyte adhesion to endothelial cells both

  2013cites this paper
• Osteoprotegerin Inhibits Calcification of Vascular Smooth Muscle Cell via Down Regulation of the Notch1-RBP-Jκ/Msx2 Signaling Pathway

  2013cites this paper
• Peroxisome Proliferator-Activated Receptor c Ligands Retard Cultured Vascular Smooth Muscle Cells Calcification Induced by High Glucose

  2013cites this paper
• TRAIL-Deficiency Accelerates Vascular Calcification in Atherosclerosis via Modulation of RANKL

  2013cites this paper
• Peroxisome Proliferator-Activated Receptor γ Ligands Retard Cultured Vascular Smooth Muscle Cells Calcification Induced by High Glucose

  2013cites this paper
• Osteoprotegerin as a Marker of Atherosclerosis in Diabetic Patients

  2013cites this paper
• trans-10,cis-12 conjugated linoleic acid promotes bone formation by inhibiting adipogenesis by peroxisome proliferator activated receptor-γ-dependent mechanisms and by directly enhancing osteoblastogenesis from bone marrow mesenchymal stem cells.

  2013cites this paper
• 4-O-Carboxymethyl Ascochlorin Causes ER Stress and Induced Autophagy in Human Hepatocellular Carcinoma Cells*

  2012cites this paper
• Osteoprotegerin and diabetes-associated pathologies.

  2011cites this paper
• The role of the osteoprotegerin/RANKL/RANK system in diabetic vascular disease.

  2011cites this paper
• The Expression and Regulation of Bone-acting Cytokines in Human Peripheral Adipose Tissue in Organ Culture

  2011cites this paper
• Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner.

  2011cites this paper
• Cardiovascular , Pulmonary , and Renal Pathology Paigen Diet – Fed Apolipoprotein E Knockout Mice Develop Severe Pulmonary Hypertension in an Interleukin-1 – Dependent Manner

  2011cites this paper
• Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus

  2011cites this paper
• Rosiglitazone decreases plasma levels of osteoprotegerin in a randomized clinical trial with type 2 diabetes patients.

  2011cites this paper
• Serum Osteoprotegerin, a Potential Novel Marker of Systemic Inflammation: The Influence of Obesity, Insulin Sensitivity and Oral Glucose Loading on its Circulating Concentrations

  2010cites this paper
• Thiazolidinediones Up-regulate Insulin-like Growth Factor-1 Receptor via a Peroxisome Proliferator-activated Receptor γ-Independent Pathway*

  2010cites this paper
• PPARs and the Cardiovascular System

  2009cites this paper
• Ostéoprotégérine : un nouvel acteur dans la pathologie vasculaire du patient diabétique ?

  2009cites this paper
• Osteoprotegerin, vascular calcification and atherosclerosis.

  2009cites this paper
• Ghrelin inhibits early osteogenic differentiation of C3H10T1/2 cells by suppressing Runx2 expression and enhancing PPARγ and C/EBPα expression

  2009cites this paper
• Mesenchymal stem cells-derived vascular smooth muscle cells release abundant levels of osteoprotegerin

  2009cites this paper
• Acute hyperinsulinemia decreases plasma osteoprotegerin with diminished effect in type 2 diabetes and obesity.

  2009cites this paper
• Peroxisome proliferator‐activated receptor γ (PPAR) agonism reduces the insulin‐stimulated increase in circulating interleukin‐6 in GH replaced GH‐deficient adults

  2009cites this paper
• Role of full-length osteoprotegerin in tumor cell biology

  2009cites this paper
• Interaction between Angiotensin II, Osteoprotegerin, and Peroxisome Proliferator-Activated Receptor-γ in Abdominal Aortic Aneurysm

  2008cites this paper
• Thiazolidinediones inhibit the growth of PC12 cells both in vitro and in vivo.

  2008cites this paper
• Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo.

  2007cites this paper
• Estrogen signaling in stroke : genetic and experimental studies

  2007cites this paper
• Osteoprotegerin and bone mineral density in hemodialysis patients

  2006cites this paper
• An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction.

  2006cites this paper
• The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease

  2006cites this paper
• The role of the TRAIL/TRAIL receptors system in hematopoiesis and endothelial cell biology.

  2006cites this paper
• Endothelial function and biochemical vascular markers in first-degree relatives of type 2 diabetic patients: the effect of exercise training.

  2006cites this paper
• Plasma osteoprotegerin levels are associated with glycaemic status, systolic blood pressure, kidney function and cardiovascular morbidity in type 1 diabetic patients.

  2006cites this paper
• Bedeutung von RANK-Ligand und Osteoprotegerin für den Knochenstoffwechsel

  2006cites this paper
• Circulating osteoprotegerin levels are associated with age, waist-to-hip ratio, serum total cholesterol, and low-density lipoprotein cholesterol levels in healthy Korean women.

  2005cites this paper
• Osteoporosis and Vascular Calcification: Lesson from OPG KO Mice

  2005influential citation
• Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies.

  2005cites this paper
• Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation.

  2005cites this paper
• Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-α

  2005cites this paper
• The Cardioprotective Effects of Preconditioning with Endotoxin, but Not Ischemia, Are Abolished by a Peroxisome Proliferator-Activated Receptor-γ Antagonist

  2005cites this paper
• Receptor activator of nuclear factor кB ligand (RANKL) versus osteoprotegerin (OPG): the yin and yang of joint integrity

  2004cites this paper
• 15d-prostaglandin J2 reduces multiple organ failure caused by wall-fragment of Gram-positive and Gram-negative bacteria.

  2004cites this paper
• The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.

  2004cites this paper
• THE PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-γ LIGAND 15-DEOXYD12,14 PROSTAGLANDIN J2 REDUCES THE ORGAN INJURY IN HEMORRHAGIC SHOCK

  2004cites this paper
• Osteoprotegerin Is a Risk Factor for Progressive Atherosclerosis and Cardiovascular Disease

  2004cites this paper
• Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy.

  2004cites this paper
• Interferon Regulatory Factor-1 Mediates PPAR&ggr;-Induced Apoptosis in Vascular Smooth Muscle Cells

  2004cites this paper
• Regulation of Vascular Calcification by Osteoclast Regulatory Factors RANKL and Osteoprotegerin

  2004cites this paper
• Activation of PPARgamma increases PTEN expression in pancreatic cancer cells.

  2003cites this paper
• Novel Aspects on RANK Ligand and Osteoprotegerin in Osteoporosis and Vascular Disease

  2003cites this paper
• Peroxisome proliferator-activated receptors and the cardiovascular system.

  2003cites this paper
• Activation of PPARγ increases PTEN expression in pancreatic cancer cells

  2003cites this paper